

DT03 Rec'd PCT/PTO 07 JUN 2004

FORM PTO-1300 (REV. 10-2003)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (if known, see 37 CFR 1.5)	
INTERNATIONAL APPLICATION NO. <i>PCT/1302/05516</i>		INTERNATIONAL FILING DATE <i>10 Dec. 2003</i>		PRIORITY DATE CLAIMED <i>10 Dec. 2001</i>	
TITLE OF INVENTION <i>The Method of Treating Cancer</i>					
APPLICANT(S) FOR DO/EO/US <i>Dr. Khamar Bakulesh Maratkar et. al</i>					

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
- ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
- ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
- ☐ The US has been elected (Article 31).
- ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - ☒ is attached hereto (required only if not communicated by the International Bureau).
 - ☐ has been communicated by the International Bureau.
 - ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - ☐ is attached hereto.
 - ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
- ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - ☐ are attached hereto (required only if not communicated by the International Bureau).
 - ☐ have been communicated by the International Bureau.
 - ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - ☐ have not been made and will not be made.
- ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

- ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- ☐ A preliminary amendment.
- ☐ An Application Data Sheet under 37 CFR 1.76.
- ☐ A substitute specification.
- ☐ A power of attorney and/or change of address letter.
- ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
- ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
- ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
- ☐ Other items or information:

U.S. APPLICATION NO. (1.137) 10/502417		INTERNATIONAL APPLICATION NO.		ATTORNEYS DOCKET NUMBER	
---	--	-------------------------------	--	-------------------------	--

21. ☐ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$1080.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$920.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$770.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$730.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT -

Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	36 - 20 =	16	x \$18.00	\$	288.00
Independent claims	- 3 =		x \$86.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$290.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	418.00

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

SUBTOTAL -

Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

TOTAL NATIONAL FEE =

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

TOTAL FEES ENCLOSED -

	Amount to be refunded:	\$
	charged:	\$

CALCULATIONS PTO USE ONLY

a. ☐ A check in the amount of \$ 418.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. _____. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Cadila Pharmaceuticals Ltd
C/o Karmarati Americas
1335 Rockville Pike
Suite 240, Rockville
MD 20852, USA

13 March 2008

SIGNATURE _____

Dr B. M. Karmarati

NAME _____

REGISTRATION NUMBER _____

7 Jun. 2004 18:35

DIRECTOR'S OFFICE CPL BHAT

No. 40/502417

DT-12 Rec'd PCT/PTO 07 JUN 2004



"Cadila Corporate Campus" Sarkhej - Dholka Road, Bhat, Ahmedabad-382 210, Gujarat (India)
Phone : (02718) 225001 (15 Lines) • Fax : 225039

June 4, 2004

U.S Patent and Trademark Office
USPTO Contact Centre (UCC)
Crystal Plaza 3, Room 2C02
P.O. Box 1450
Alexandria, VA 22313-1450

Fax : 703-305-7786

Sub: Our patent application no. PCT/IB02/05516 entitled "The Method of Treating Cancer" - National Phase in US

Dear Sir,

We have filed patent application with PCT on 10.12.2002 and has been given application no. PCT/IB02/05516 which has been since published by WIPO having number WO 03/049667 A2, entitled "The Method of treating cancer".

We would like to enter into National Phase in United States for the said application. We request you kindly to undertake all required procedure on our behalf. We are forwarding following material in respect of the same.

WO publication no. WO 03/049667 A2 of PCT application no. PCT/IB02/05516 & International Search Report.

We hope this will suffice the purpose. You are requested to undertake all formalities for submission, including paying official registration fees and send us your invoice for the same.

With regards,

Yours truly,


Dr. Bakulosh M. Khamar

Encl: Copy of Publications of PCT/IB02/05516 and PCT/IB02/05515 alongwith international search report.

P.S. check for fees is being forwarded separately.

RECEIVED

JUN - 8 2004

USPTO
CONTACT-CENTER

BEST AVAILABLE COPY